Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Has results × Valganciclovir × Clear all

Phase

Status

Sponsor Class

OTHER_GOV 1 OTHER 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Kaposi 1 Immune Reconstitution Inflammatory Syndrome 1 Acquired Immunodeficiency Syndrome 1

Interventions

ibritumomab tiuxetan 1 ferric maltol 1 Valganciclovir 1 Tranexamic Acid 1 Tacrolimus 1 Sirolimus 1 Moxibustion 1 Low-Level Light Therapy 1 Infliximab 1 Bevacizumab 1 Alemtuzumab 1 Acupuncture Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

Phase 2 Completed

40 enrolled 6 charts

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡